Iguratimod treatment reduces disease activity in early primary Sjögren’s syndrome

https://www.tandfonline.com/doi/abs/10.1080/14397595.2020.1789335?journalCode=imor20 https://www.ncbi.nlm.nih.gov/pubmed/32613869?dopt=Abstract TITLE: Iguratimod treatment reduces disease activity in early primary Sjögren’s syndrome: an open-label pilot study. DESCRIPTION: Iguratimod treatment reduces disease activity in early primary Sjögren’s syndrome: an open-label pilot study. Mod Rheumatol. 2020 Jul 02;:1-13 Authors: Chen H, Qi X, Li Y, Wu Q, Shi Q, Wang L, Li J, Zhao L, Zhang […]

The efficacy and mechanism for action of iguratimod in primary Sjögren’s syndrome patients

https://link.springer.com/article/10.1007%2Fs10792-020-01490-6 https://www.ncbi.nlm.nih.gov/pubmed/32607949?dopt=Abstract TITLE: The efficacy and mechanism for action of iguratimod in primary Sjögren’s syndrome patients. DESCRIPTION: Related Articles The efficacy and mechanism for action of iguratimod in primary Sjögren’s syndrome patients. Int Ophthalmol. 2020 Jul 01;: Authors: Jiang W, Zhang L, Zhao Y, He X, Hu C, Liu Y Abstract PURPOSE: Primary Sjögren’s syndrome […]